Owkin is a company.
Owkin has raised $51.0M across 4 funding rounds.
Key people at Owkin.
Owkin has raised $51.0M in total across 4 funding rounds.
Owkin has raised $51.0M in total across 4 funding rounds.
Owkin's investors include .406 Ventures, 4BIO Capital, Eight Roads Ventures, F-Prime Capital Partners, Scale Venture Partners, Cathay Innovation, Granite Asia, FJ Labs, Frst, Makers Camp, Oleg Tscheltzoff, Pierre Valade.
Key people at Owkin.
Owkin is a French-American AI biotechnology company founded in 2016, specializing in precision medicine through AI-driven drug discovery, clinical trial acceleration, and diagnostic tools.[1][2][6] It serves biopharmaceutical companies, hospitals, universities, and researchers by solving the complexity of biological data—using federated learning and multimodal patient datasets to identify new treatments, de-risk trials, and develop diagnostics while preserving data privacy.[1][2][4] Key products include the OWKIN Socrates platform for federated learning, Owkin K (an agentic AI operating system with biological reasoning models like Owkin Zero), and specialized companies like MSIntuit (digital pathology AI for cancer biomarkers) and developer of OKN4395 (a Phase 1 EP2/EP4/DP1 inhibitor).[1][6][7][8] Owkin demonstrates strong growth through partnerships with Sanofi, BMS, and MSD, plus initiatives like the MOSAIC multi-omics atlas for cancer research across seven indications.[2][6]
Owkin was co-founded in 2016 by Thomas Clozel, MD—a former assistant professor in clinical onco-hematology with expertise in patient care—and Gilles Wainrib, PhD—a pioneer in machine learning applied to biology.[1][4][6] The idea emerged from their recognition that vast, siloed patient data in hospitals could unlock precision medicine if analyzed collaboratively without compromising privacy, leading to the development of federated learning as a core technology.[1][2][4] Early traction came from building a network of top hospitals, key opinion leaders (KOLs), and multimodal datasets, enabling partnerships with pharma giants and the launch of tools like OWKIN Socrates for drug development in oncology.[1][6] Pivotal moments include founding MOSAIC, the world's largest spatial multi-omics atlas, and incubating ventures like Bioptimus for universal biology AI models.[2][7]
Owkin rides the TechBio wave, blending AI with wet-lab biology to decode complex diseases amid exploding multimodal data from genomics, proteomics, and pathology.[2][3][7] Timing is ideal as privacy regulations (e.g., GDPR, HIPAA) and data silos hinder traditional research, while federated learning and agentic AI enable secure, scalable insights—positioning Owkin as a leader in precision oncology and beyond.[1][4][9] Market forces like rising clinical trial costs (over 90% failure rates) and demand for biomarkers favor its de-risking tools, influencing the ecosystem by breaking data walls through hospital networks and pharma collaborations (Sanofi, BMS, MSD).[2][6] It accelerates the shift to "biological AGI," standardizing AI operating systems for biotech R&D and fostering open innovation via atlases like MOSAIC.[7][9]
Owkin is poised to dominate TechBio with Owkin K evolving into a universal biology OS, powering more AI-native drugs like OKN4395 and diagnostics while expanding BASI (Biology Super Intelligence).[7][8][9] Trends like multimodal foundation models, agentic AI for causal biology insights, and global data networks will propel its growth, potentially capturing pharma workflows as trials succeed and partnerships scale.[2][6][9] Influence may evolve from enabler to ecosystem orchestrator, incubating more spinouts and standardizing privacy-first AI—ultimately transforming patient outcomes from data complexity to precision therapies, as envisioned since its 2016 origins.[1][6]
Owkin has raised $51.0M across 4 funding rounds. Most recently, it raised $25.0M Series A in May 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2020 | $25.0M Series A | .406 Ventures, 4BIO Capital, Eight Roads Ventures, F-Prime Capital Partners, Scale Venture Partners | |
| Mar 1, 2019 | $13.0M Series A | .406 Ventures, 4BIO Capital, Cathay Innovation, Eight Roads Ventures, F-Prime Capital Partners, Granite Asia, Scale Venture Partners | |
| Jan 1, 2018 | $11.0M Series A | Cathay Innovation, FJ Labs, Frst, Granite Asia, Makers Camp, Oleg Tscheltzoff, Pierre Valade | |
| Oct 1, 2016 | $2.0M Seed | Acequia Capital, B Capital Group, Firstminute Capital, Pioneer Square Labs, Third Kind Ventures, Johann "Hansi" Hansmann, Martin Varsavsky, Rudy Gadre, Sujal Patel |
